 | |
| Legal status | |
|---|---|
| Legal status | |
| Identifiers | |
| |
| CAS Number | |
| PubChemCID | |
| ChemSpider | |
| UNII | |
| CompTox Dashboard(EPA) | |
| Chemical and physical data | |
| Formula | C23H23N3O |
| Molar mass | 357.457 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
MN 18 is anindazole-basedsynthetic cannabinoid that is anagonist for thecannabinoid receptors, withKi values of 45.72 nM atCB1 and 11.098 nM atCB2 andEC50 values of 2.028 nM at CB1 and 1.233 nM at CB2,[1] and has been sold online as adesigner drug.[2][3] It is the indazole core analogue ofNNE1. Given the known metabolic liberation (and presence as an impurity) ofamantadine in the related compoundAPINACA, it is suspected that metabolic hydrolysis of the amide group of MN-18 may release1-naphthylamine, a knowncarcinogen. MN-18 metabolism has been described in literature.[4][5]
MN-18 is banned in Sweden.[when?][6]On 15 September 2014 the Turkey government banned the sale of MN-18.[7]
 | Thiscannabinoid related article is astub. You can help Wikipedia byexpanding it. |
